Evidence map›Paper›PMID 27998041›Full record

SynthesisArthritis care & research2017

Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.

Laura C Cappelli, Anna Kristina Gutierrez, Clifton O Bingham, Ami A Shah

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Arthritis care & research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 176 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
176citing papers in PubMed, 11 pooled it
16.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

176 citing papers in PubMed, 11 syntheses or guidelines pooled it, 388 citations in OpenAlex.

  1. Diagnosis and management of immune checkpoint inhibitor-induced dry mouth and salivary gland dysfunction in oncology patients: a systematic review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Trial
  13. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Observational
  19. The management of rheumatic immune related adverse events.Best practice & research. Clinical rheumatology · 2026
    Review
  20. Pain spectrum in immune checkpoint inhibitor-related adverse events: evolution, characteristics and management challenges based on bibliometrics.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article

116 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Laura C CappelliJohns Hopkins University, Baltimore, Maryland.
Anna Kristina GutierrezJohns Hopkins University, Baltimore, Maryland.
Clifton O BinghamJohns Hopkins University, Baltimore, Maryland.
Ami A ShahJohns Hopkins University, Baltimore, Maryland.
Johns Hopkins University · US

Funding

Sample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, Antony Rosen · 2016 to 2026
$8.9M
Phenotype-Specific Immune Responses in the Systemic VasculitidesP30AR053503 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI BINGHAM, CLIFTON O · 2006 to 2015
$6.4M
Summer Research Training in Aging for Medical StudentsT35AG026758 · NIA · JOHNS HOPKINS UNIVERSITY · PI Stephanie Nothelle, Sevil Yasar · 2005 to 2026
$1.9M
Cancer, Autoantigens, and Scleroderma Investigating the ConnectionK23AR061439 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI SHAH, AMI AALOK · 2012 to 2016
$699k
NIAMS NIH HHS K23 AR061439NIAMS NIH HHS P30 AR053503NIAMS NIH HHS P30 AR070254NIA NIH HHS T35 AG026758
6 · The paper itself

Abstract

objectiveImmune checkpoint inhibitors (ICIs) are improving prognoses in advanced stage cancers, but they also lead to immune-related adverse events (IRAEs). IRAEs targeting many organ systems have been reported, but musculoskeletal and rheumatic IRAEs have not been well-characterized. We systematically reviewed published literature on musculoskeletal and rheumatic IRAEs to better understand prevalence and clinical characteristics.

methodsMedline and CENTRAL databases were searched for articles reporting rheumatic and musculoskeletal IRAEs secondary to ICI treatment. After screening abstracts and full texts in duplicate, clinical features, prevalence, and treatment data were extracted and summarized.

resultsA total of 1,725 unique abstracts were screened; 231 contained original data and were about ICIs and went to full-text screening. Fifty-two of these contained information about musculoskeletal or rheumatic IRAEs or about treatment with ICIs in preexisting autoimmune disease. Of these, 33 were clinical trials, 3 were observational studies, and 16 were case reports or series. Arthralgia prevalence in clinical trials ranged 1-43%, and myalgia was reported in 2-20%. Arthritis was reported in 5 of 33 clinical trials, and vasculitis was reported in only 2. One observational study and 3 case reports described patients with preexisting autoimmune disease treated with ICIs. Case reports included development of inflammatory arthritis, vasculitis, myositis, and lupus nephritis.

conclusionArthralgia and myalgia have been reported commonly in patients treated with ICIs. The prevalence of rheumatic IRAEs such as inflammatory arthritis, vasculitis, and sicca syndrome is less clear from current evidence. There is limited observational and case-level evidence describing ICI use in patients with preexisting autoimmune disease.

Indexed as

Antibodies, MonoclonalAntineoplastic AgentsArthralgiaArthritis, RheumatoidClinical Trials as TopicHumansImmunologic FactorsImmunosuppressive AgentsImmunotherapyMyalgiaAntibodies, MonoclonalAntineoplastic AgentsImmunologic FactorsImmunosuppressive Agents

Identifiers

PMID27998041
PMCPMC5478477
OpenAlexW2565782504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.